Phase 3CompletedHealthspan endpoint

Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects (EBBINGHAUS)

A Double-Blind, Placebo Controlled, Multicenter Study to Assess the Effect of Evolocumab on Cognitive Function in Patients With Clinically Evident Cardiovascular Disease and Receiving Statin Background Lipid Lowering Therapy: A Study for Subjects Enrolled in the FOURIER (Study 20110118) Trial

Sponsor
Amgen (Industry)
Enrollment
1,974 enrolled
Conditions
Dyslipidemia
Interventions
Evolocumab; Placebo; Background Statin Therapy
Ages
adults, older adults
Registry
NCT02207634, EUCTR2014-001976-75

Full record on ClinicalTrials.gov

From the registry

This study evaluated change over time in neurocognitive testing in patients receiving statin therapy in combination with evolocumab (AMG 145), compared with patients receiving statin therapy in combination with placebo.

Primary outcomes

  • Mean Change From Baseline in Spatial Working Memory Strategy Index of Executive Function (6-8 Boxes) Z Score

History

  1. Results first posted

  2. Last registry update

  3. Primary completion

  4. Started

  5. Registered